Subscribe X
Back to Top



November 19, 2013 by Sandra Steingard, MD

Tapering Neuroleptics: Two Year Results

Sandra_Steingard_MDAs I have described previously, I have been tracking my experience with tapering neuroleptic drugs in my clinical practice. With all of the people I see who are stable on a particular dose of a neuroleptic drug, I discuss the risks of long-term use of these drugs. We also discuss the potential benefits.  This conversation varies from person to person. We take into account what has happened in the past,  how he is doing now, and what she has to lose if her past problems were to re-emerge.  If a person wants to taper, I suggest slow reduction; 25-30% every 3-6 months.  I keep track of who chooses to taper and who does not.  I now have a colleague who is doing the same in her practice.   Together, we are following 112 individuals. We presented our data in a poster presentation at the Institute of Psychiatric Services in October, 2013.

Read More

August 28, 2013 by Thomas Insel, MD

NIMH Director’s Blog: Antipsychotics: Taking the Long View

One of the first lessons I received as a psychiatrist-in-training 35 years ago was the value of antipsychotic medications. These medicines have been available for the treatment of psychosis for over half a century, beginning with the prototype first generation drug chlorpromazine (Thorazine) and now extending to some 20 different compounds, including several second-generation medications, often called “atypical antipsychotics.” Symptoms such as hallucinations, delusions, and paranoia are reduced reliably by these drugs. Although these symptoms can be frightening and dangerous for patients, family members, and providers, antipsychotics safely and effectively help people through the crisis of acute psychosis.

However, the long-term management of chronic mental illness is another matter. Recently, results from several studies have suggested that these medications may be less effective for the outcomes that matter most to people with serious mental illness: a full return to well-being and a productive place in society.

Read More

August 22, 2013 by William V. Bobo, MD et al | JAMA

Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth


Importance  The increased prescribing of antipsychotics for children and youth has heightened concerns that this practice increases the risk of type 2 diabetes mellitus.

Objective  To compare the risk of type 2 diabetes in children and youth 6 to 24 years of age for recent initiators of antipsychotic drugs vs propensity score–matched controls who had recently initiated another psychotropic medication.

Read More

Related Blogs

  • Dr. David Healy

    Dr. David Healy

    Dr. Healy is a professor of psychiatry at Cardiff University in Wales and an author on the history of pharmaceuticals and government regulation.
  • Mad In America: Robert Whitaker

    Mad In America: Robert Whitaker

    Journalist and author Bob Whitaker distills the latest in pharmaceutical and mental health research.
  • Selling Sickness

    Selling Sickness

    Creating a new partnership movement to challenge the selling of sickness.
  • Kathy Brous

    Kathy Brous

    A serial of Kathy's recovery journey as an adult with attachment disorder.
  • Nev Jones

    Nev Jones

    Exploring the intersections of psychiatry, philosophy, neuroscience, cultural theory, critical community psychology and the mad/user/survivor movement.
  • 1boringoldman


    Retired psychiatrist and raconteur offers insightful analysis of the day's events from the woods of Georgia.